Abstracts tagged "methotrexate (MTX)"

Abstract Number: 2483 • 2012 ACR/ARHP Annual Meeting
Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Roger K. Wolff⁴, Gail S. Kerr⁵, Andreas M. Reimold⁶, Grant W. Cannon⁷, Ted R. Mikuls⁸ and Liron Caplan⁹, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴University of Utah, Salt Lake City, UT, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the cornerstone medication in the treatment of rheumatoid arthritis (RA). While MTX has been associated with a number of adverse…
Abstract Number: 1328 • 2012 ACR/ARHP Annual Meeting
The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Yoshinobu Koyama¹, Kazunori Hase², Daisuke Hidaka², Shuji Nagano³, Toshiyuki Ota³ and Ayumi Uchino², ¹Division of Rheumatology, Okayama Red Cross General Hospital, Okayama, Japan, ²Iizuka Hospital, Iizuka, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose: Although data are conflicting with regard to the clinical utility of MTX polyglutamates (PGs) measurements as a predictor of the efficacy or toxicity in…
Abstract Number: 317 • 2012 ACR/ARHP Annual Meeting
Fatty Acid Profiling: Potential New Biomarkers in Juvenile Idiopathic Arthritis (pilot study)
Weng Tarng Cham¹, Enzo Ranieri², Janice Fletcher² and Christina A. Boros³, ¹Paediatric Rheumatology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia, ²Chemical Pathology and Molecular Genetics, SA Pathology, North Adelaide, SA 5006, Australia, ³Paediatrics, University of Adelaide/Women's and Children's Hospital, Adelaide, Australia
Background/Purpose: The prostanoids are a family of biologically active lipids derived from the 20-carbon essential fatty acids (LCPUFA) all of which are involved in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].